Cochrane's audited annual report: income of £10.5m, of which royalties from the Cochrane Library published by John Wiley & Sons were £7.05m, and a statement of its conflict-of-interest and commercial-sponsorship rules. It also states that Cochrane members cannot be employed by pharmaceutical or device companies.
Cochrane entities are not permitted to accept funds from commercial sponsors or commercial sources that have a financial interest in the topic areas covered by the Cochrane Library.
p. 15
Cochrane's audited annual report: income of £10.5m, of which royalties from the Cochrane Library published by John Wiley & Sons were £7.05m, and a statement of its conflict-of-interest and commercial-sponsorship rules. It also states that Cochrane members cannot be employed by pharmaceutical or device companies. Bearing nuance: the policy bar on industry money is real and stated in Cochrane's own audited accounts, but Cochrane's income is overwhelmingly derived from royalties paid by a commercial publisher (Wiley) – the report calls this its 'core income' and a 'major income risk'. So 'free from commercial influences' is true for research funding and false as a description of Cochrane's revenue model. Approved by the Board 16 July 2025. Study type: other.
